Randomised comparison of ABVD with two multi-drug regimens (MDRs) in the treatment of advanced Hodgkin lymphoma (HL): Initial results of the UKLG LY09 study (ISRCTN 97144519).

被引:0
|
作者
Johnson, PM
Radford, J
Cullen, MH
Jan, W
Sydes, MR
Ryder, D
Smith, P
Clawson, S
Stenning, SP
Hancock, B
机构
[1] Southampton Gen Hosp, Southampton SO9 4XY, Hants, England
[2] Christie Hosp, Manchester, Lancs, England
[3] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[4] MRC, Clin Trials Unit, Canc Div, London, England
[5] BNLI, Canc Res UK, Clin Trials Ctr, London, England
[6] Weston Pk Hosp, Sheffield, S Yorkshire, England
[7] Marie Curie Sklodowska Mem Canc Ctr, Hematooncol Intens Care Dept, Warsaw, Poland
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
84
引用
收藏
页码:27A / 27A
页数:1
相关论文
共 10 条
  • [1] Randomised controlled trial of ABVD vs. two multi-drug regimens (MDRs) for advanced Hodgkin's lymphoma (HL): Initial results of UKLG LY09 (ISRCTN97144519).
    Hancock, B
    Radford, J
    Cullen, MH
    Walewski, J
    Sydes, MR
    Ryder, D
    Smith, P
    Clawson, S
    Stenning, SP
    Johnson, PM
    BRITISH JOURNAL OF CANCER, 2004, 91 : S1 - S1
  • [2] A randomised controlled trial of ABVD vs two multi-drug regimens for advanced Hodgkin lymphoma - Updated results of UKLG LY09
    Radford, JA
    Cullen, MH
    Hancock, BW
    Walewski, J
    Sydes, MR
    Ryder, D
    Smith, P
    Clawson, S
    Stenning, SP
    Johnson, PWM
    ANNALS OF ONCOLOGY, 2005, 16 : 51 - 51
  • [3] Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519)
    Owadally, W. S.
    Sydes, M. R.
    Radford, J. A.
    Hancock, B. W.
    Cullen, M. H.
    Stenning, S. P.
    Johnson, P. W. M.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 568 - 573
  • [4] Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin's Lymphoma (HL): Data from UKLG LY09 (ISRCTN97144519)
    Johnson, P. W. M.
    Sydes, M. R.
    Stenning, S. P.
    Cullen, M. H.
    Radford, J. A.
    Hancock, B. W.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 68 - 69
  • [5] Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)
    Johnson, PWM
    Radford, JA
    Cullen, MH
    Sydes, MR
    Walewski, J
    Jack, AS
    MacLennan, KA
    Stenning, SP
    Clawson, S
    Smith, P
    Ryder, D
    Hancock, BW
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9208 - 9218
  • [7] Consolidation Radiotherapy Is Associated with Improved Outcomes after Chemotherapy for Advanced Hodgkin Lymphoma: Analysis of Results from the UKLG LY09 Trial (ISRCTN97144519)
    Johnson, Peter W. M.
    Sydes, Matthew R.
    Radford, John
    Cullen, Michael
    Stenning, Sally
    Hancock, Barry
    BLOOD, 2008, 112 (11) : 143 - 143
  • [8] Consolidation Radiotherapy in Patients With Advanced Hodgkin's Lymphoma: Survival Data From the UKLG LY09 Randomized Controlled Trial (ISRCTN97144519)
    Johnson, Peter W. M.
    Sydes, Matthew R.
    Hancock, Barry W.
    Cullen, Michael
    Radford, John A.
    Stenning, Sally P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3352 - 3359
  • [9] The ULKG LY09 advanced Hodgkin's disease trial: Initial data on treatment intensity and toxicity (ISRCTN 97144519).
    Johnson, P
    Radford, J
    Cullen, M
    Sydes, M
    Ryder, D
    Smith, P
    Clawson, S
    Stenning, S
    Hancock, B
    BRITISH JOURNAL OF CANCER, 2002, 86 : S25 - S25
  • [10] Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244
    Johnson, Peter W. M.
    Horwich, Alan
    Jack, Andrew
    Mead, Graham
    Hancock, Barry
    Smith, Paul
    Qian, Wendi
    Patrick, Philippa
    Pettitt, Andrew
    Cunningham, David
    Hoskin, Peter
    BLOOD, 2008, 112 (11) : 144 - 144